Artificial Cartilage Implant Market Report 2025

The artificial cartilage implant market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to the expanding aging population, the rising prevalence of osteoarthritis, an increase in sports-related injuries, growing demand for minimally invasive procedures, and the rising number of orthopedic surgeries.

The artificial cartilage implant market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the expanding geriatric population, rising obesity rates, increasing demand for faster recovery, growing health awareness, and the rising interest in regenerative therapies. Key trends expected during this period include the use of 3D bioprinting for cartilage, the development of smart implants, the application of nanotechnology to implant surfaces, the creation of hybrid implants with integrated drug delivery, and the adoption of robotic-assisted implant surgeries.

The increasing prevalence of osteoarthritis is expected to drive the growth of the artificial cartilage implant market in the coming years. Osteoarthritis is a degenerative joint disorder marked by the gradual breakdown of cartilage, which results in pain, stiffness, and limited mobility. Its rising incidence is largely attributed to increasing obesity, as excess body weight places additional stress on joints, accelerating cartilage wear and joint deterioration. Artificial cartilage implants serve as replacements for damaged cartilage, helping restore smooth joint surfaces, reduce friction, alleviate pain, and improve mobility while slowing further joint degeneration. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based health agency, reported that around 2.1 million Australians, or 8.3% of the population, were living with osteoarthritis, contributing to 2,314 deaths (8.9 per 100,000) in 2022. Therefore, the growing prevalence of osteoarthritis is fueling the expansion of the artificial cartilage implant market.

Leading companies in the artificial cartilage implant market are focusing on developing innovative products such as three-dimensional (3D) printed knee implants to improve joint compatibility and deliver durable solutions for osteoarthritis patients. These implants are patient-specific replacements created layer by layer using advanced 3D printing technology, ensuring a precise anatomical fit, enhanced joint function, and faster recovery. For instance, in July 2025, Nanochon, a US-based medical device startup, introduced Chondrograft, which was approved by Health Canada. Designed to replace damaged or lost cartilage in the knee, it uses a synthetic, high-performance material that mimics the porosity and structure of natural cartilage, allowing it to integrate with the body and stimulate new tissue growth. This off-the-shelf solution offers a minimally invasive alternative to traditional procedures such as knee replacement, aiming to restore knee cartilage function while delaying or avoiding the need for more invasive surgeries.

In November 2023, Smith+Nephew, a UK-based medical technology company, acquired CartiHeal Ltd. for $330 million. This acquisition expanded Smith+Nephew’s orthopedic and sports medicine portfolio by incorporating CartiHeal’s advanced cartilage repair technologies. The deal enhances minimally invasive joint preservation treatments, targeting early-stage cartilage damage and meeting the growing demand for innovative osteoarthritis therapies. CartiHeal Ltd. is an Israel-based manufacturer of artificial cartilage implants.

Major players in the artificial cartilage implant market are Johnson & Johnson, B. Braun Melsungen AG, Medtronic plc, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stryker Corporation, Arthrex Inc., Conmed Corporation, Orthofix Medical, Corin Group, Anika Therapeutics Inc., Vericel Corporation, Tissue Regenix Group plc, Nusurface, Uteshiya Medicare Inc., Sparta Biomedical Inc., BioPoly LLC, Orthocell Ltd, Sartorius CellGenix GmbH, CytoSeek Limited.

North America was the largest region in the North America market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial cartilage implant market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the artificial cartilage implant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

An artificial cartilage implant is a synthetic medical device designed to replicate the structure and function of natural cartilage. It provides a durable, biocompatible layer between bones in a joint, helping to reduce friction, absorb impact, and restore mobility. These implants are used to relieve pain and improve joint function in patients with cartilage damage caused by injury or degenerative conditions.

The primary types of artificial cartilage implants include biological implants, synthetic implants, composite implants, and smart implants. Biological implants are medical devices derived from natural tissues or biomaterials, created to replace or support damaged body parts. Artificial cartilage implants are available in various product types, such as upper extremity joints, lower extremity joints, and vertebral joints, and are distributed through multiple channels including direct sales, online retail, distributors, and specialty clinics. They are applied in a wide range of procedures, such as knee replacement, hip replacement, shoulder reconstruction, and ankle replacement, and are used by different end users, including hospitals, orthopedic clinics, ambulatory surgical centers, research institutes, and others.

The artificial cartilage implant market research report is one of a series of new reports that provides artificial cartilage implant market statistics, including artificial cartilage implant industry global market size, regional shares, competitors with an artificial cartilage implant market share, detailed artificial cartilage implant market segments, market trends and opportunities, and any further data you may need to thrive in the artificial cartilage implant industry. The artificial cartilage implant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial cartilage implant market consists of sales of hydrogel-based implants, three-dimensional (3D) bioprinted implants, hybrid implants, and nanostructured implants. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.